MTSR Fundamental Analysis - METSERA INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to MTSR. MTSR was compared to 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MTSR as it has an excellent financial health rating, but there are worries on the profitability. MTSR does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MTSR has reported negative net income.

1.2 Ratios

The Return On Assets of MTSR (-55.41%) is comparable to the rest of the industry.

MTSR has a Return On Equity (-78.90%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-55.41%
ROE	-78.9%
ROIC	N/A

ROA(3y)-26.59%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MTSR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MTSR has about the same amout of shares outstanding than it did 1 year ago.

The debt/assets ratio for MTSR is higher compared to a year ago.

2.2 Solvency

MTSR has an Altman-Z score of 8.22. This indicates that MTSR is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of MTSR (8.22) is better than 84.03% of its industry peers.

There is no outstanding debt for MTSR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	8.22

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.26 indicates that MTSR has no problem at all paying its short term obligations.

MTSR has a Current ratio (5.26) which is comparable to the rest of the industry.

A Quick Ratio of 5.26 indicates that MTSR has no problem at all paying its short term obligations.

MTSR has a Quick ratio (5.26) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.26
Quick Ratio	5.26

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MTSR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -342.97%.

EPS 1Y (TTM)-342.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -19.26% on average over the next years. This is quite bad

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-0.63%

EPS Next 2Y-4.31%

EPS Next 3Y-19.26%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MTSR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTSR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MTSR's earnings are expected to decrease with -19.26% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.31%

EPS Next 3Y-19.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MTSR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

METSERA INC

NASDAQ:MTSR (8/8/2025, 8:00:02 PM)

After market: 30.03 -0.37 (-1.22%)

30.4

-0.49 (-1.59%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-28 2025-07-28/amc

Earnings (Next)N/A N/A

Inst Owners78.06%

Inst Owner Change-0.07%

Ins Owners0.91%

Ins Owner Change0%

Market Cap3.19B

Analysts86

Price Target58.48 (92.37%)

Short Float %10.87%

Short Ratio10.33

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-8.61%

Min EPS beat(2)-18.8%

Max EPS beat(2)1.59%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)10%

PT rev (3m)17.02%

EPS NQ rev (1m)-2.2%

EPS NQ rev (3m)12.33%

EPS NY rev (1m)2.13%

EPS NY rev (3m)4.87%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	7.11
P/tB	9.11
EV/EBITDA	N/A

EPS(TTM)-3.71

EYN/A

EPS(NY)-3.55

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS4.28

TBVpS3.34

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-55.41%
ROE	-78.9%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-26.59%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.26
Quick Ratio	5.26
Altman-Z	8.22

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-342.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y-0.63%

EPS Next 2Y-4.31%

EPS Next 3Y-19.26%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-571.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-133.45%

EBIT Next 3Y-58.08%

EBIT Next 5YN/A

FCF growth 1Y-182.54%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-182.65%

OCF growth 3YN/A

OCF growth 5YN/A

METSERA INC (MTSR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens